About Immutep
Immutep is a publicly listed company based in Sydney (Australia) founded in 2001, and was acquired by Prima Biomed in October 2014. Therapeutics for autoimmune and oncology indications are developed. Its chief executive, as recorded, is Marc Voigt. Immutep offers products and services including Eftilagimod Alpha and LAG-3 Immunotherapies. Its focus areas include Life Sciences, Immunotherapy, Diversified and Immunology.
Company details
Immutep was founded in 2001 and is headquartered in Sydney, Australia. Focus is placed on the biotechnology sector, where therapeutics for autoimmune diseases and oncology are developed. The lead product, Eftilagimod alpha, targets metastatic cancers, while IMP761 serves as a monoclonal antibody for immunological conditions and LAG525 addresses autoimmune disorders. Operations emphasize clinical-stage immunotherapy solutions.
- Headquarters Sydney, Australia
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website immutep.com
- Social LinkedIn X Facebook YouTube
- Acquired by Prima Biomed (Oct 2014)
- Latest Funding Round$44.87M (USD), Post-IPO
Jun 2021
- InvestorsGSK
& 5 more
- Acquired byPrima Biomed
(Oct 2014)
Products & Services of Immutep
Immutep offers a comprehensive portfolio of products and services, including Eftilagimod Alpha and LAG-3 Immunotherapies.
LAG-3 agonist designed to enhance immune response against cancer.
Therapies targeting immune regulation for autoimmune diseases.
Apps and channels of Immutep
its YouTube channel Immutep has 186 subscribers and 30 videos.
Videos from Immutep
The most watched videos on Immutep's YouTube channel, Immutep (186 subscribers). Click a video to play it here.
More on Immutep.
Funding Insights of Immutep
- Total Rounds 7
- Last Round Post-IPO — $44.87M
- First Round $5.37M
(Mar 2018)
- Investors Count 5
All 7 funding rounds of Immutep with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $44.87M | Post-IPO | – | – | – |
| Aug 2020 | Grant | – | – | ||
| Sep 2019 | $5.02M | Post-IPO | – | – | |
| Jul 2019 | $520,674 | Post-IPO | – | – | – |
| Dec 2018 | $5.2M | Debt – Conventional | – | – | |
| Apr 2018 | $4.85M | Post-IPO | – | – | – |
| Mar 2018 | $5.37M | Post-IPO | – | – |
6 investors in total: 6 institutional.
Investors in Immutep
Immutep has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include GSK, Platinum Asset Management and Prima Biomed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ridgeback Capital is focused on healthcare and life science investments. | ridgebackcap.com | New York, United States | ||
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
| gcaaltium.com | ||||
International equity investment management services are provided globally. | 1994 | platinum.com.au | Sydney, Australia | |
Research funding and evaluation are supported by the organization. | arc.gov.au | Canberra, Australia | ||
Immunotherapeutics based on the LAG-3 immune control mechanism and dendritic cell therapy for cancer. | 1987 | primabiomed.com.au | Armadale, Australia |
Investor details for Immutep
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immutep
31 people are tracked at Immutep (9 in leadership, 9 in board & advisors, 13 in team).
| Name | Role | Group |
|---|---|---|
Marc Voigt | CEO | Leadership |
Deanne Miller | COO, General Counsel & Company Secretary | Leadership |
Claudia Jacoby | Director of Manufacturing | Leadership |
James Flinn | Intellectual Property & Innovation Director | Leadership |
Virginie Lobrégat-Duriez | Director of Clinical Operations | Leadership |
Luca Perjesi | Medical Director | Leadership |
Frédéric Triebel | Chief Scientific Officer & Chief Medical Officer | Leadership |
David Fang | Finance Director & Assistant Company Secretary | Leadership |
Dávid Winkler MD | Associate Medical Director | Leadership |
Martine J. Piccart | Advisor | Board & advisors |
Martin Forster | Clinical Advisor | Board & advisors |
Scott Antonia | Clinical Advisor | Board & advisors |
Leisha A Emens | Clinical Advisor | Board & advisors |
Hans Wildiers | Clinical Advisor | Board & advisors |
Russell Howard | Non-Executive Chairman | Board & advisors |
Lis Boyce | Non-Executive Director | Board & advisors |
Salah-Eddin Al-Batran | Advisor | Board & advisors |
Pete Meyers | Non-Executive Director & Deputy Chairman | Board & advisors |
Anurag Parihar | Senior Manager | Team |
Mariia Liebau | Office Manager | Team |
11 more people are available in the full profile.
Complete people profiles for Immutep
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Immutep
Immutep is a publicly listed company on the ASX with ticker symbol IMM in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Jun 2012
- Listed onFRA: YP1B
- Listed entityIMMUTEP LIMITED
- Exchange sectorHealth technology
Timeline of Immutep
5 dated milestones of Immutep across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Immutep is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Prima Biomed.
- Funding First funding round of $5.4M.
- Funding Latest funding round, Post-IPO, of $44.9M.
Web traffic of Immutep
The website of Immutep (immutep.com) receives about 8.9K visits a month and ranks #2,562,349 among all websites worldwide, #3,509 in Biotechnology and Pharmaceuticals.
- Monthly visits8.9K
▼ 1.2% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,562,349
among all websites
- Category rank#3,509
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.5
- Average visit9 sec
- DevicesDesktop 22% · Mobile 78%
Websites whose visitors overlap most with Immutep. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| immunicum.se | 100% | View details | |||
jnjmedicalconnect.com | jnjmedicalconnect.com | 72% | #559,591 | – | |
| aditxt.com | 33% | 2.9K | #6,429,138 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immutep
Complete news archive for Immutep
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immutep
Immutep was founded in 2001 and raised its 1st funding round 17 years after it was founded.
Immutep is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Marc Voigt is the CEO of Immutep, as recorded in our data.
Immutep was founded in 2001 and is headquartered in Sydney, Australia. Focus is placed on the biotechnology sector, where therapeutics for autoimmune diseases and oncology are developed. The lead product, Eftilagimod alpha, targets metastatic cancers, while IMP761 serves as a monoclonal antibody for immunological conditions and LAG525 addresses autoimmune disorders. Operations emphasize clinical-stage immunotherapy solutions.
Immutep offers Eftilagimod Alpha and LAG-3 Immunotherapies.
Yes, Immutep is publicly traded on ASX under the ticker symbol IMM.
Immutep has 6 investors. Key investors include GSK, Platinum Asset Management, Prima Biomed, GCA Altium, and Ridgeback Capital.
Yes. Immutep was acquired by Prima Biomed in October 2014.